• Glycine, Ferritin Turnover, and Lens Iron Homeostasis

  2026-09-11

  The reference study identifies excessive lysosome-dependent ferritin degradation as a driver of iron imbalance in UVB-stressed lens epithelial cells. It further shows that glycine acts through lysosomal PAT1, Nrf2, NCOA4, and PCBP2-linked iron handling, offering a mechanistic framework for studying ferroptosis-related cataract development.

• Cytochalasin B: From Actin Probe to Translation

  2026-09-10

  Cytochalasin B is more than an actin-disrupting reagent: it is a decision-making tool for separating cytoskeletal dependence from downstream cellular effects. This article connects its mechanism to Spiroplasma entry, assay design, oncology translation, and evidence-led experimental strategy.

• Resazurin Cell Viability Assay in Osteobiology

  2026-09-10

  The Resazurin Cell Viability Assay Kit provides a sensitive way to separate treatment-related cytotoxicity from altered osteoblast activity. This article applies the assay to PORCN inhibition and sclerosteosis research while explaining metabolic-readout limitations and practical validation strategies.

• 3-Hydroxybutyrate (BHBA) in Ketosis Assays

  2026-09-09

  3-hydroxybutyrate (BHBA) gives researchers a defined way to model ketone-body signaling, ferroptosis resistance, and metabolic-to-chromatin coupling in cultured cells. This guide translates stroke-neuroprotection findings into practical dose-response workflows, controls, and troubleshooting strategies for in vitro ketosis models.

• Palbociclib (PD0332991) Mechanism and Research Use

  2026-09-09

  Palbociclib, also called PD0332991, is a selective CDK4/6 inhibitor that suppresses retinoblastoma-protein phosphorylation and produces cell cycle G0/G1 arrest. Its documented preclinical activity spans renal cell carcinoma research and Colo-205 xenograft models, while its clinical relevance is established in hormone-receptor-positive, HER2-negative advanced breast cancer.

• PPACK Dihydrochloride: Causal Assay Design

  2026-09-08

  PPACK Dihydrochloride enables researchers to separate direct thrombin effects from downstream platelet purinergic signaling. This article develops a causal assay framework that combines irreversible thrombin inhibition with insights from NF449 receptor pharmacology.

• Dabigatran (Pradaxa): Mechanism & Research Use

  2026-09-08

  Dabigatran, also known as Pradaxa’s active moiety, is a reversible direct thrombin inhibitor that blocks free and fibrin-bound thrombin. Its research value lies in controlled thrombin inhibition assays and coagulation function tests, while clinical use requires formulation-specific labeling and renal impairment dose adjustment.

• Dacarbazine: From DNA Damage to Translation

  2026-09-07

  Dacarbazine is an antineoplastic chemotherapy drug whose translational value extends beyond its established role in malignant melanoma, Hodgkin lymphoma, and sarcoma. This thought-leadership perspective connects DNA alkylation biology with better in vitro response measurements, activation-aware model selection, and more decision-ready oncology workflows.

• Carbenoxolone disodium: Practical Lab Guide

  2026-09-07

  Carbenoxolone disodium is a research reagent for probing 11β-hydroxysteroid dehydrogenase activity, glucocorticoid access, and gap junction communication in cell or tissue workflows. It is best used as an exploratory mechanistic perturbation, not as a selective target-validation compound or an in vivo efficacy treatment without additional evidence and controls.

• Dacarbazine Workflows for DNA Damage Research

  2026-09-05

  Build reproducible Dacarbazine experiments around fresh solution handling, schedule-aware DNA damage readouts, and matched vehicle controls. The workflow connects melanoma, lymphoma, and sarcoma models with a clinically informed approach to chemotherapy-associated nausea research without confusing bench findings with clinical dosing.

• Ibrutinib (PCI-32765): BTK Assay Logic

  2026-09-04

  Ibrutinib (PCI-32765) is a covalent BTK inhibitor for dissecting B-cell receptor signaling, chronic lymphocytic leukemia research, and immune-cell assays. This guide adds a genotype-aware framework, using ATRX-deficient glioma research to clarify how kinase-response findings should—and should not—be translated across disease models.

• Aclacinomycin A: Mechanism and Research Use

  2026-09-04

  Aclacinomycin A, also called Aclarubicin, is an anthracycline DNA damage inducer that inhibits topoisomerase I and II. Its reported cytotoxicity, apoptosis signaling, proteasome activity, and storage requirements support controlled research use with explicit assay and exposure documentation.

• 3D Gold Nanocluster Arrays for Reproducible SERS

  2026-09-03

  The reference study presents a polymer pen lithography route for constructing ordered three-dimensional gold nanocluster arrays with adjustable geometry. By combining patterned polyethylenimine scaffolds with electrostatic nanoparticle assembly, the authors obtain strong SERS enhancement, low reported variability, and a practical framework for tuning substrate architecture.

• Baricitinib (LY3009104, INCB028050) Assay Guide

  2026-09-03

  A scenario-based guide to using Baricitinib (LY3009104, INCB028050), SKU A4141, in cell viability, proliferation, and signaling assays. It connects low-nanomolar JAK1/2 pharmacology with practical decisions about dosing, DMSO formulation, controls, interpretation, and vendor reliability.

• HyperScribe Co-transcription mRNA Synthesis Kit Plus

  2026-09-02

  Generate ARCA-capped, polyadenylated transcripts for translation studies, RNAi workflows, structure-function experiments, and vaccine research. This practical guide connects reproducible T7 transcription with the design logic of an HCC mRNA nanovaccine study, while separating upstream RNA quality from downstream delivery performance.

8594 records 2/573 page Previous Next 12345 下5页 Last page